Item 2.02. Results of Operations and Financial Condition.

On January 10, 2022, at the virtual 40th Annual J.P. Morgan Healthcare Conference, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, are providing a corporate update.

The presentation includes information regarding the Company's preliminary (unaudited) U.S. net product sales of EYLEA® (aflibercept) Injection of approximately $5.79 billion for the full year 2021 (based on preliminary (unaudited) fourth quarter 2021 U.S. net product sales of EYLEA of approximately $1.54 billion).

The presentation also includes information regarding the Company's preliminary (unaudited) U.S. net product sales of REGEN-COV®(casirivimab and imdevimab) of approximately $5.82 billion for the full year 2021 (based on preliminary (unaudited) fourth quarter 2021 U.S. net product sales of REGEN-COV of approximately $2.29 billion).




Item 7.01.   Regulation FD Disclosure.

The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference herein. A copy of the presentation referenced in Item 2.02 is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 7.01.

The information included in Item 2.02 and the information included or incorporated in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.



  99.1       Presentation by Leonard S. Schleifer, M.D., Ph.D., President and Chief
           Executive Officer of Regeneron Pharmaceuticals, Inc., and George D.
           Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of
           Regeneron Pharmaceuticals, Inc., at the virtual 40th Annual J.P. Morgan
           Healthcare Conference.

104        Cover Page Interactive Data File - the cover page XBRL tags are embedded
           within the Inline XBRL document.

© Edgar Online, source Glimpses